{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:49:00Z","timestamp":1772120940776,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018703","name":"European Innovation Council","doi-asserted-by":"publisher","award":["190144395"],"award-info":[{"award-number":["190144395"]}],"id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.iotech.2024.100738","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T15:49:28Z","timestamp":1727279368000},"page":"100738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Analyzing functional heterogeneity of effector cells for enhanced adoptive cell therapy applications"],"prefix":"10.1016","volume":"24","author":[{"given":"AC.","family":"Kiel Rasmussen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.M.","family":"Hulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.L.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6.","family":"Met","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Donia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mouritzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.iotech.2024.100738_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iotech.2024.100738_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iotech.2024.100738_bib3","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iotech.2024.100738_bib4","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.iotech.2024.100738_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.iotech.2024.100738_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.iotech.2024.100738_bib7","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2024.100738_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150535","article-title":"Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma","volume":"132","author":"Kristensen","year":"2022","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.iotech.2024.100738_bib9","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.iotech.2024.100738_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.iotech.2024.100738_bib11","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.iotech.2024.100738_bib12","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s42003-021-02142-w","article-title":"A\u00a0combined approach for single-cell mRNA and intracellular protein expression analysis","volume":"4","author":"Reimegard","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.iotech.2024.100738_bib13","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/btpr.2690","article-title":"A\u00a0novel mammalian cell line development platform utilizing nanofluidics and optoelectro positioning technology","volume":"34","author":"Le","year":"2018","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.iotech.2024.100738_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/2472630319892571","article-title":"Cyto-Mine: an integrated, picodroplet system for high-throughput single-cell analysis, sorting, dispensing, and monoclonality assurance","volume":"25","author":"Josephides","year":"2020","journal-title":"SLAS Technol"},{"key":"10.1016\/j.iotech.2024.100738_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202003479","article-title":"Droplet-based combinatorial assay for cell cytotoxicity and cytokine release evaluation","volume":"30","author":"Antona","year":"2020","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.iotech.2024.100738_bib16","doi-asserted-by":"crossref","first-page":"24674","DOI":"10.1021\/acsomega.0c03264","article-title":"Droplet-based cytotoxicity assay: implementation of time-efficient screening of antitumor activity of natural killer cells","volume":"5","author":"Antona","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.iotech.2024.100738_bib17","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1039\/C9LC01261C","article-title":"Droplet encapsulation improves accuracy of immune cell cytokine capture assays","volume":"20","author":"Yuan","year":"2020","journal-title":"Lab Chip"},{"key":"10.1016\/j.iotech.2024.100738_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ymeth.2021.02.003","article-title":"Verification of CRISPR editing and finding transgenic inserts by Xdrop indirect sequence capture followed by short- and long-read sequencing","volume":"191","author":"Blondal","year":"2021","journal-title":"Methods"},{"key":"10.1016\/j.iotech.2024.100738_bib19","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/humu.24063","article-title":"Xdrop: targeted sequencing of long DNA molecules from low input samples using droplet sorting","volume":"41","author":"Madsen","year":"2020","journal-title":"Hum Mutat"},{"key":"10.1016\/j.iotech.2024.100738_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/cyto.a.22668","article-title":"Optimization of the cytokine secretion assay for human IL-2 in single and combination assays","volume":"87","author":"Deng","year":"2015","journal-title":"Cytometry A"},{"key":"10.1016\/j.iotech.2024.100738_bib21","series-title":"Application Note: Identifying highly potent TNF-\u03b1-secreting T cells using the Xdrop\u00ae single-cell format","author":"Jacobsen","year":"2022"},{"key":"10.1016\/j.iotech.2024.100738_bib22","series-title":"Application Note: Revealing and retrieving highly potent IFN-\u03b3 secretors using an Xdrop single-cell format workflow based on double-emulsion droplets","author":"Jacobsen","year":"2023"},{"key":"10.1016\/j.iotech.2024.100738_bib23","series-title":"FDA guidance for industry: potency assurance for cellular and gene therapy products","year":"2023"},{"key":"10.1016\/j.iotech.2024.100738_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1053684","article-title":"CAR-T cells are serial killers","volume":"4","author":"Davenport","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.iotech.2024.100738_bib25","series-title":"Application Note: Rapidly identifying active natural killer cells","author":"Jacobsen","year":"2023"},{"key":"10.1016\/j.iotech.2024.100738_bib26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.iotech.2024.100738_bib27","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.4049\/jimmunol.179.6.3812","article-title":"Granzyme B activity in target cells detects attack by cytotoxic lymphocytes","volume":"179","author":"Packard","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.iotech.2024.100738_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.839783","article-title":"GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD(2) and releasing inducible IL-18","volume":"13","author":"Glienke","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2024.100738_bib29","series-title":"Application Note: Revealing granzyme B secretion and cell killing dynamics in a single-cell format","author":"Petersen","year":"2024"},{"key":"10.1016\/j.iotech.2024.100738_bib30","series-title":"Cell distribution calculator","year":"2024"},{"key":"10.1016\/j.iotech.2024.100738_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074740","article-title":"CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies","volume":"13","author":"Kekre","year":"2022","journal-title":"Front Immunol"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018824000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018824000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T12:46:54Z","timestamp":1734439614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018824000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"alternative-id":["S2590018824000352"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2024.100738","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.27.595942","asserted-by":"object"}]},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyzing functional heterogeneity of effector cells for enhanced adoptive cell therapy applications","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2024.100738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100738"}}